NCT06639256 is a Phase 1/Phase 2 clinical trial of Test Product HY07121 in Safety, sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd.

Who is sponsoring NCT06639256?

NCT06639256 is sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd.

What drugs are being tested in NCT06639256?

Interventions in NCT06639256: Test Product HY07121.

What condition does NCT06639256 study?

NCT06639256 studies Safety, Tolerability, Efficacy.

Is NCT06639256 still recruiting?

NCT06639256 is currently recruiting now. Last updated 26 January 2026.

Last reviewed 2026-01-26 · How we verify

NCT06639256

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

Recruiting now Phase 1/Phase 2 Last updated 26 January 2026

What this trial tests

Phase 1/Phase 2 trial testing Test Product HY07121 in Safety in 258 participants. Currently enrolling.

Timeline

24 October 2024

Primary endpoint
1 May 2026

1 October 2026

Quick facts

Lead sponsor	Sichuan Huiyu Pharmaceutical Co., Ltd
Phase	Phase 1/Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	258
Start date	24 October 2024
Primary completion	1 May 2026
Estimated completion	1 October 2026
Sites	1 location across China

Drugs / interventions tested

Test Product HY07121 — full drug profile →

Conditions studied

Safety — all drugs for Safety →
Tolerability — all drugs for Tolerability →
Efficacy — all drugs for Efficacy →

Sponsor

Sichuan Huiyu Pharmaceutical Co., Ltd — full company profile →

Who can join

Adults 18 to 80, any sex, with Safety or Tolerability. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Dose Escalation (Part One): Incidence and Nature of Dose-Limiting Toxicity (DLT)
Time frame: 21 days during the first 3-week cycle
Dose-Limiting Toxicity (DLT) will be defined using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) criteria for Cytokine Release Syndrome (CRS).
Dose Escalation (Part One): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)
Time frame: Up to 2 years
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading
Dose Escalation (Part One): Percentage of participants experiencing Adverse Event (AE) related dose interruptions, dose delays, and dose intensity
Time frame: Up to 2 years
Occurrence of Adverse Event (AE) related dose interruptions, dose delays and dose intensity (duration of HY07121 exposure)
Dose Expansion (Part Two): Objective Response Rate (ORR)
Time frame: Up to 2 years
Proportion of participants who have a confirmed Complete Response (CR) or a Partial Response (PR)

Sponsor's own description

This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Safety

Currently open trials in the same condition.

NCT06818994 — Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced · Phase 1 · recruiting
NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
NCT06760208 — A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market · recruiting
NCT07157215 — An International Survey on the Use of NIV Outside the ICU · recruiting
NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting

Other Sichuan Huiyu Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

NCT07083323 — A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06977490 — Human Bioequivalence Study of Amphotericin B Liposome for Injection · NA · completed
NCT06895993 — Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants · Phase 1 · completed
NCT06765590 — Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer · NA · recruiting
NCT06756490 — A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06639256 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan Huiyu Pharmaceutical Co., Ltd
Last refreshed: 26 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06639256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing